Últimas noticias sobre IQVIA Hldgs (NYSE:IQV) Bolsa

IQVIA Hldgs

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings

IQVIA Holdings Inc

Piper Sandler analyst Patrick Moley initiates coverage on MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Overweight rating and announces Price Target of $34.

News

Price Target

Initiation

Analyst Ratings

MARA

Piper Sandler Initiates Coverage On MARA Holdings with Overweight Rating, Announces Price Target of $34

Compass Point analyst Casey Alexander upgrades Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) from Sell to Neutral and announces $8.25 price target.

Upgrades

HRZN

Compass Point Upgrades Horizon Tech Finance to Neutral, Announces $8.25 Price Target

Oppenheimer analyst Steve Lichtman initiates coverage on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform rating and announces Price Target of $275.

Oppenheimer Initiates Coverage On Penumbra with Outperform Rating, Announces Price Target of $275

On Monday, December 16th, U.S. markets closed mixed, with the Nasdaq reaching a record high and the S&amp;P 500 rising as investors anticipated the Federal Reserve&#8217;s policy decision and a likely rate cut. Gains in the consumer sector offset weaker manufacturing data. Investor sentiment remained upbeat, driven by hopes for easing rates and economic resilience.
On the economic front, the NY Empire State Manufacturing Index dropped sharply to 0.20 in December from 31.2 the previous month, missing expectations. Meanwhile, the S&amp;P Global services PMI rose to 58.5 in December, while the manufacturing PMI fell to 48.3 from 49.7 in November.
Most S&amp;P 500 sectors closed lower, led by materials, energy, and healthcare, while consumer discretionary and communication services outperformed, ending higher.
The Dow Jones Industrial Average was down 0.25% and closed at 43,717.48, the S&amp;P 500 closed higher by 0.38% to 6,074.08, while the Nasdaq Composite rose 1.24% to finish at 20,173.89.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 declined 0.13% and ended the session at 39,410.00, led by losses in the Shipbuilding, Warehousing, and Precision Instruments sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.78% and ended the day at 8,314.00, led by gains in the Industrials, IT, and A-REITs sectors.</li>
<li>India&#8217;s Nifty 50 slid 1.41% to 24,320.30, and Nifty 500 was down 1.19%, closing at 23,075.15.</li>
<li>China&#8217;s Shanghai Composite fell 0.73% to close at 3,361.49, while the Shenzhen CSI 300 gained 0.26%, finishing the day at 3,922.03.</li>
<li>Hong Kong&#8217;s Hang Seng was down 0.48% and closed the session at 19,700.48.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was up 0.32%.</li>
<li>Germany&#8217;s DAX gained 0.18%.</li>
<li>France&#8217;s CAC rose 0.28%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.75%.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 1.44% at $69.69/bbl, and Brent was down 0.72% at $73.39/bbl.</li>
<li>Oil prices fell due to weak Chinese economic data and caution ahead of the Fed&#8217;s interest rate decision.</li>
<li>Natural Gas rose 0.65% to $3.235.</li>
<li>Gold was trading lower by 0.53% at $2,655.99, Silver was down 1.16% to $30.700, and Copper fell 1.14% to $4.1435.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were down 0.35%, S&amp;P 500 futures fell 0.25% and Nasdaq 100 futures slid 0.04%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. Dollar Index was up 0.17% to 107.03, USD/JPY was down 0.22% at 153.81, and USD/AUD rose 0.47% to 1.5770.</li>
<li>The U.S. dollar remained strong ahead of the Federal Reserve&#8217;s expected rate cut, supported by robust economic data and higher yields.</li>
</ul>
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Mostly Lower, Europe Markets Up As Dollar Strengthens Ahead Of Fed Rate Decision - Global Markets Today While US Slept

Oppenheimer analyst Steve Lichtman initiates coverage on Inari Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) with a Outperform rating and announces Price Target of $75.

NARI

Oppenheimer Initiates Coverage On Inari Medical with Outperform Rating, Announces Price Target of $75

Correction: Telsey Advisory Group analyst Joe Feldman upgrades Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) from Market Perform to Outperform and raises the price target from $21 to $26. (Rating changed)

Correction: Telsey Advisory Group Upgrades Albertsons Companies to Outperform, Raises Price Target to $26 (Rating changed)

Telsey Advisory Group analyst Joe Feldman maintains Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) with a Outperform and raises the price target from $21 to $26.

Telsey Advisory Group Maintains Outperform on Albertsons Companies, Raises Price Target to $26

Mizuho analyst Vijay Rakesh upgrades Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Neutral to Outperform and raises the price target from $230 to $515.

TSLA

Mizuho Upgrades Tesla to Outperform, Raises Price Target to $515

This approximate gross Bitcoin mining revenue figure is based upon a Bitcoin price of $106,000.

GPUS

Hyperscale Data Says Subsidiary ACS Mined 20 Bitcoin During November 2024 Resulting In Annualized Run Rate Of $26M In Gross Bitcoin Mining Revenue

Elon Musk has expressed admiration for Alphabet Inc.&#8217;s (NASDAQ: GOOG0 (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) <a href="https://www.benzinga.com/24/12/42514620/googles-veo-2-and-imagen-3-set-new-standards-for-ai-creativity">new AI video tool</a>, Veo 2, as it enters the competitive landscape against OpenAI&#8217;s Sora.
What Happened: On Monday, Google introduced Veo 2, a cutting-edge AI video tool, alongside its enhanced Imagen 3 image models.
Veo 2 boasts features like up to 4K resolution, extended video lengths, shallow depth of field, and specific lens types.&nbsp;
The company's CEO Sundar Pichai showcased videos generated by Veo 2 on X, formerly Twitter, demonstrating its potential.&nbsp;
See Also: <a href="https://www.benzinga.com/24/12/42499106/microsofts-iphone-file-sharing-apples-watch-ultra-1-2-billion-lawsuit-and-more-this-week-in-appleverse?itm_source=parsely-api">Microsoft&#8217;s iPhone File Sharing, Apple&#8217;s Watch Ultra, $1.2 Billion Lawsuit And More: This Week In Appleverse</a>
Replying to him, xAI founder Musk said, &#8220;Looks impressive,&#8221; referring to the videos generated by the model.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Looks impressive
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1868814824626700318?ref_src=twsrc%5Etfw">December 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk also shared a post by prominent investor Jason Calacanis, who stated that both Google's Gemini and xAI's Grok models have now "reached parity, and in some cases are much better," than OpenAI's ChatGPT.
Calacanis noted that his use of all three models—Google's Gemini, Grok, and ChatGPT—had shifted dramatically over the past month, with Google's tools now handling more than 50% of his queries, a sharp increase from the previous 90% reliance on ChatGPT.
Calacanis said, "It's now a data and UI game, and I think Reddit, X/Twitter, and Google's dataset will trounce OpenAI's lack of data."
His statement underscores the growing belief that Google's data advantages and advanced AI tools could soon outpace OpenAI in several key areas.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Google/Gemini and Grok have reached parity, and in some cases are much better, than ChatGPT I use all three, every day, at least 50-100x … ChatGPT went from 90% of my queries last month to &lt; 50% It's now a data and UI game, and I think Reddit, X/twitter and google's… <a href="https://t.co/4tOEBz1ffB">https://t.co/4tOEBz1ffB</a>
&mdash; @jason (@Jason) <a href="https://twitter.com/Jason/status/1868710433139376358?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: Previously, Marc Andreessen commended <a href="https://www.benzinga.com/tech/24/12/42501018/marc-andreessen-praises-openais-sora-video-model-we-may-have-basically-just-solved-the-fundamental-challenge-of-robotics">OpenAI's Sora video model</a> for tackling a major challenge in robotics by enabling the creation of realistic video.
He highlighted the model's capability to produce 3D-realistic video from text inputs, effectively simulating intricate elements such as lighting and reflections that are crucial for real-world navigation.
However, apart from OpenAI's Sora, Google's latest model competes with several other companies.
Earlier this year, Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) launched its AI-driven video tool aimed at advertisers, entering the market alongside Adobe's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) Firefly <a href="https://www.benzinga.com/markets/equities/24/09/40819405/adobe-shakes-up-video-editing-with-ai-powered-creation-tools-whats-on-the-cards">Video Model</a>.
In October 2024, Meta Platforms Inc. (META) also unveiled Movie Gen, a new tool <a href="https://www.benzinga.com/top-stories/24/10/41188250/metas-movie-gen-brings-ai-powered-video-audio-creation-to-all">designed to create videos</a>, images, and audio from text prompts.
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42495758/elon-musk-finds-an-unlikely-ally-in-mark-zuckerbergs-meta-in-his-fight-against-sam-altmans-openai?itm_source=parsely-api">Elon Musk Finds An Unlikely Ally In Mark Zuckerberg&#8217;s Meta In His Fight Against Sam Altman&#8217;s OpenAI</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Tech

ADBE

AMZN

GOOGL

Elon Musk Reacts After Sundar Pichai Shares Veo 2 As Google Looks To Challenge OpenAI's Sora In AI Video Race: 'Looks Impressive'

SkyAlyne Partners With CGI To Deliver IT Solutions For Canada's 25-Year Future Aircrew Training Program

Through this existing collaboration, Evonik's proprietary biodegradable long-acting PLGA (RESOMER) microparticle formulation was used for SIL-204, Silexion's next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. By leveraging Evonik's formulation expertise, Silexion aims to deliver sustained-release RNAi therapy, allowing for more effective targeting of KRAS mutations—one of the most challenging genetic drivers in oncology.

Biotech

Health Care

General

SLXN

Silexion Therapeutics Revealed Its Ongoing Collaboration With Evonik For The Development Of An Advanced siRNA Formulation Aimed At Enhancing Cancer Treatment Efficacy

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the ongoing AFM24-102 trial of AFM24/atezolizumab combination therapy in heavily pretreated NSCLC patients. Results continue to demonstrate meaningful clinical activity in both NSCLC EGFRwt and EGFRmut patients with good tolerability. In addition, the Company reported findings from a post-hoc exposure-response analysis in patients treated with 480 mg AFM24 showing higher AFM24 exposure is associated with significantly better response rates, improved PFS and overall survival (OS). Based on these data, the future development program for AFM24 will use a dose of 720 mg weekly, a dose that has already been successfully tested in the phase 1 study of AFM24 showing a manageable safety profile.

AFMD

Affimed Reports Results for Cancer Therapy in NSCLC Patients

Management

Brazil Potash Appoints Mayo Schmidt As Executive Chairman Of Its Board, Effective January 6, 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Buy and lowers the price target from $20 to $13.

Reiteration

FHTX

HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Lowers Price Target to $13

Jefferies analyst Omar Nokta maintains Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Buy and lowers the price target from $26 to $20.

Jefferies Maintains Buy on Frontline, Lowers Price Target to $20

Morgan Stanley analyst Angel Castillo upgrades WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) from Equal-Weight to Overweight and raises the price target from $40 to $50.

Morgan Stanley Upgrades WillScot Holdings to Overweight, Raises Price Target to $50

Jefferies analyst Omar Nokta maintains Hafnia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAFN#NYSE">HAFN</a>) with a Buy and lowers the price target from $8 to $6.5.

HAFN

Jefferies Maintains Buy on Hafnia, Lowers Price Target to $6.5

Guidance

Merrill Lynch & Strategic Return Notes for Select 10 Index

Reported Earlier, Maison Solutions Reiterates FY25 Guidance: Revenues $120M - $125M, Net Income Positive

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and maintains $30 price target.

ANNX

HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target

RBC Capital analyst Sean Dodge reiterated a Buy rating on IQVIA Holdings (IQV – Research Report) yesterday and set a price target of $270.00. The c...

IQVIA Holdings (IQV) Gets a Buy from RBC Capital

In a report released today, Shlomo Rosenbaum from Stifel Nicolaus maintained a Buy rating on IQVIA Holdings (IQV – Research Report), with a price t...

IQVIA Holdings (IQV) Receives a Buy from Stifel Nicolaus

In a report released today, Elizabeth Anderson CFA from Evercore ISI reiterated a Buy rating on IQVIA Holdings (IQV – Research Report), with a pric...

IQVIA Holdings (IQV) Receives a Buy from Evercore ISI

IQVIA: Will This Beaten-Down Stock Bounce Back? 3 Things To Know

Mizuho Securities analyst Ann Hynes has reiterated their bullish stance on IQV stock, giving a Buy rating yesterday. Ann Hynes's rating is based on...

IQVIA Holdings: Promising Growth Trajectory and Strategic AI Integration Support Buy Rating

In a report released today, Jailendra Singh from Truist Financial reiterated a Buy rating on IQVIA Holdings (IQV – Research Report), with a price t...

IQVIA Holdings (IQV) Gets a Buy from Truist Financial

IQVIA Holdings: Share Price Disconnected From Growth Outlook

Truist lowered the firm's price target on Iqvia (IQV) to $261 from $265 and keeps a Buy rating on the shares. The company's Investor Day presentati...

Iqvia price target lowered to $261 from $265 at Truist

BofA lowered the firm's price target on Iqvia (IQV) to $235 from $255 and keeps a Buy rating on the shares. The Life Sciences Tools sector underper...

Iqvia price target lowered to $235 from $255 at BofA

ICON: A High Probability Of Success In The Uncertain R&D Process

FTRE

ICLR

Press Releases

IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group

IQVIA Reports Second-Quarter 2024 Results

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024

Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative

IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award

IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™

IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024

IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day

IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024

AVAI

EXAI

RXRX

TWST

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

IQVIA Hldgs

Noticias

Últimas noticias sobre IQVIA Hldgs (NYSE:IQV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL